BerGenBio ASA (BRRGF) News Today → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Free BRRGF Stock Alerts $0.03 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesStock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative March 20, 2024 | finance.yahoo.comBerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutationFebruary 7, 2024 | finance.yahoo.comBerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory InfectionsJanuary 31, 2024 | lse.co.ukGram Car Carriers Asa Share Price (GCC.OL)December 2, 2023 | sg.finance.yahoo.comBerGenBio ASA (BRRGF) stock historical prices & data – Yahoo FinanceNovember 18, 2023 | morningstar.comBerGenBio ASA BGBIONovember 14, 2023 | finance.yahoo.comBerGenBio Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comBerGenBio Announces Data from Biomarker Analyses in 2L NSCLCOctober 31, 2023 | finance.yahoo.comBerGenBio Announces Poster Presentation at Upcoming SITC MeetingOctober 23, 2023 | finance.yahoo.comNew Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO MeetingOctober 16, 2023 | finance.yahoo.comAdditional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meetingAugust 23, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on BerGenBio AS (BRRGF)August 22, 2023 | finance.yahoo.comBerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung CancerAugust 15, 2023 | bbc.co.ukCoronation concert ballot misleading, says regulator ASAMay 26, 2023 | finance.yahoo.comBerGenBio ASA: Approval and publication of prospectus for the preferential Rights IssueMay 16, 2023 | markets.businessinsider.comBerGenBio AS (BRRGF) Gets a Buy from H.C. WainwrightApril 25, 2023 | finance.yahoo.comBerGenBio ASA: Proposed partially underwritten rights issueMarch 9, 2023 | finance.yahoo.comBerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 MutationsFebruary 17, 2023 | finanznachrichten.deBerGenBio ASA: BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsFebruary 16, 2023 | finance.yahoo.comBerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateFebruary 15, 2023 | finance.yahoo.comBerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsNovember 15, 2022 | finance.yahoo.comBerGenBio reports third quarter 2022 financial results and provides business updateOctober 25, 2022 | prnewswire.comBerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva ASOctober 11, 2022 | finance.yahoo.comBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 MutationsSeptember 27, 2022 | finance.yahoo.comBERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTSSeptember 10, 2022 | reuters.comBGBIO.OL - Bergenbio ASA | Stock Price & Latest News | ReutersAugust 23, 2022 | finance.yahoo.comBerGenBio reports second quarter and half year 2022 financial results and provides business updateApril 11, 2022 | finance.yahoo.comBerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical OfficerApril 7, 2022 | finance.yahoo.comBERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021February 16, 2022 | finance.yahoo.comBERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021January 27, 2022 | finance.yahoo.comBerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 PatientsJanuary 21, 2022 | nasdaq.comBRRGF Real-Time QuotesJanuary 18, 2022 | nasdaq.comBRRGF Price/Earnings & PEG RatiosNovember 9, 2021 | finance.yahoo.comBergenbio Presents Pre-clinical and Clinical Data on Bemcentinib in STK11-positive NSCLC at SITC Annual Meeting 2021November 9, 2021 | finance.yahoo.comBerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC) Get BerGenBio ASA News Delivered to You Automatically Sign up to receive the latest news and ratings for BRRGF and its competitors with MarketBeat's FREE daily newsletter. Email Address The 1,000X Crypto Playbook (Ad)Chris Rowe has created a “Crypto Playbook” that anyone can follow… potentially turning small investments into pers #1 Crypto for 2024, completely FREE. BRRGF Media Mentions By Week BRRGF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BRRGF News Sentiment▼0.000.54▲Average Medical News Sentiment BRRGF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BRRGF Articles This Week▼00▲BRRGF Articles Average Week Get BerGenBio ASA News Delivered to You Automatically Sign up to receive the latest news and ratings for BRRGF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ARTLW News Today ASCLF News Today AWKNF News Today AXIM News Today BCTXW News Today CLVLY News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BRRGF) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldObama’s Forever Term [exposed]Porter & CompanyDems have chosen Biden replacement?Paradigm PressDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge Alerts348 million Americans lives to END as we know it?The Oxford ClubDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BerGenBio ASA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
